Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
MDGL Stock Chart & Stats
$495.88
-$1.78(-0.55%)
At close: 4:00 PM EST
$495.88
-$1.78(-0.55%)
Day’s Range― - ―
52-Week Range$265.00 - $505.05
Previous CloseN/A
Volume47.78K
Average Volume (3M)354.29K
Market Cap
$11.11B
Enterprise Value$9.54B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$346.40M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Mar 04, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.08
Shares Outstanding22,711,420
10 Day Avg. Volume521,761
30 Day Avg. Volume354,288
Financial Highlights & Ratios
PEG Ratio-1.47
Price to Book (P/B)8.70
Price to Sales (P/S)36.44
P/FCF Ratio-14.36
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue12.89
Enterprise Value/Gross Profit13.53
Enterprise Value/Ebitda-34.41
Forecast
1Y Price Target
$523.71Price Target Upside5.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-10.8
Revenue Forecast (FY)$942.99M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRezdiffra's revenue of $287M significantly surpassed both analyst and market expectations.
Market ExpansionRezdiffra is now the first and only approved MASH therapy in Europe with labeling that does not specify a biopsy requirement for treatment.
Product LaunchRezdiffra is the first approved drug for MASH with early launch metrics indicating high demand and potential for upside from continued strong launch.
Bears Say
Competitive PressureCompetitive challenges are increasing, which may limit the upside potential for Madrigal's stock.
Financial ChallengesThe net loss of $114M was influenced by a substantial one-time expense for a licensing agreement.
Pricing And Reimbursement ConcernsCost-conscious single payer systems in the EU may not reimburse Rezdiffra near its current annual Wholesale Acquisition Cost of approximately $49k.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $265.00 and its highest was $505.05 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $11.11B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 112 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$5.08 earnings per share for the quarter, missing the consensus estimate of -$2.285 by -$2.795.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -0.62.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 22,711,420 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$5.08 in its last earnings report, missing expectations of -$2.285. Following the earnings report the stock price went up 7.831%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$523.71 (5.61% Upside)
$523.71 (5.61% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 202.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.39%
12-Months-Change
Fundamentals
Return on Equity
-41.22%
Trailing 12-Months
Asset Growth
26.95%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead product candidate, resmetirom, is being evaluated for its potential to treat non-alcoholic steatohepatitis (NASH), a progressive liver disease. Madrigal Pharmaceuticals operates predominantly in the biotechnology and pharmaceuticals sector, leveraging cutting-edge research and development to address significant unmet medical needs.
MDGL Company Deck
MDGL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong quarter for Madrigal Pharmaceuticals, driven by the successful launch of Rezdiffra and robust financial health. However, increased operating expenses and ongoing challenges with payer contracting highlight areas of concern. Additionally, competitive pressures from other entrants in the MASH market could impact future growth. Overall, the sentiment is cautiously optimistic.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$523.71
▲(5.61% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
20.04% Insiders
24.81% Mutual Funds
0.03% Other Institutional Investors
41.12% Public Companies and Individual Investors